Autoregulation of 5-fluorouracil metabolism

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1623-1627

  McLeod, H L ^a   Sludden, J ^a   Hardy, S C ^a   Lock, R E ^a   Hawksworth, G M ^a   Cassidy, J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

5 flurouracil; Dihydropyrimidine dehydrogenase; Enzyme inhibition; Metabolism

Indexed keywords

FLUOROURACIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOREGULATION; DRUG DEGRADATION; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER METABOLISM; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDOTES; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HEMOSTASIS; HUMANS; LEUCOVORIN; LIVER; MALE; MONOCYTES; OXIDOREDUCTASES; RATS; TESTOSTERONE;

EID: 0032169768     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00175-0     Document Type: Article

References (34)

1. 1. Gonzalez FJ, Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase. Trends Pharmacol Sci 1995, 16, 325-327.
2. 2. Heggie GD, Sommadossi J-P, Cross DS, Fluster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987, 47, 2203-2206.
3. 3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989, 16, 215-237.
4. 4. Wattanatorn W, McLeod HL, MacKlon F, Reid M, Kendle KE, Cassidy J. A comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cell in patients with colorectal cancer. Pharmacotherapy 1997, 17, 881-886.
5. 5. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994, 12, 1291-1295.
6. 6. Trump DL, Egorin MJ, Forrest A, Willson JKV, Remick S, Tutsch KD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 1991, 9, 2027-2035.
7. 7. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996, 77, 441-451.
8. 8. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996, 98, 610-615.
9. 9. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 1991, 68, 499-501.
10. 10. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53, 5433-5438.
11. 11. McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharm 1996, 41, 425-427.
12. 12. Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995, 13, 1663-1670.
13. 13. McLeod HL, Sludden J, Murray GI, et al. Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998, 77, 461-465.
14. 14. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990, 50, 197-201.
15. 15. Harris BE, Song R, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 1988, 37, 4759-4762.
16. 16. Vankuilenburg ABP, Poorter RL, Peters GJ, Vanlenthe H, Stroomer AEM, Vangennip AH. Circadian variation of dihydropyrimidine dehydrogenase (DPD), uridine phosphorylase (Up), beta-alanine (Beta-Ala) and 5-fluorouracil, (5-Fu) during continuous infusion (Ci) fluoropyrimidines (Fp). Eur J Cancer 1995, 31A(S5), 954.
17. 17. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin J Pharmacol Ther 1994, 56, 190-201.
18. 18. Fujimoto S, Kikugawa M, Kaneko M, Tamaki N. Role of dihydropyrimidine dehydrogenase in the uridine nucleotide metabolism in the rat liver. J Nutr Sci Vitamin 1992, 38, 39-48.
19. 19. Sludden J, Hardy SC, Jackson FC, Hawksworth GM, Cassidy J, McLeod HL. Influence of cancer chemotherapy on rat liver dihydropyrimidine dehydrogenase (submitted).
20. 20. Fujimoto S, Matsuda K, Kikugawa M, Kaneko M, Tamaki N. Effect of vitamin B2 efficiency on rat liver dihydropyrimidine dehydrogenase activity. J Nutr Sci Vitamin 1991, 37, 89-98.
21. 21. Davis LE, Lenkinski RE, Shinkwin MA, Kressel HY, Daly JM. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer 1993, 72, 3715-3722.
22. 22. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JC, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996, 32A, 2148-2154.
23. 23. Lowry OH, Rosebrough FAC, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
24. 24. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. Evidence for its haemoprotein nature. J Biol Chem 1964, 239, 2370-2378.
25. 25. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P450. Arch Biochem Biophys 1987, 255, 27-41.
26. 26. Funae Y, Imaoka S. Purification and characterisation of liver microsomal cytochrome P450 from untreated rats. Biochem Biophys Acta 1987, 926, 349-358.
27. 27. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992, 52, 2899-2902.
28. 28. Scheyer RD, Cramer JA, Mattson RH. A pharmacodynamic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 1994, 83, 491-494.
29. 29. Baker DK, Relling MV, Pui C-H, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992, 10, 311-315.
30. 30. Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, Erlichman C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988, 44, 622-628.
31. 31. Takimoto CH, Voeller DB, Strong JM, Anderson L, Chu E, Allegra CJ. Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA. J Biol Chem 1993, 268, 21438-21442.
32. 32. Levine M, Bellward GR. Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex. Drug Metab Disp 1995, 23, 1407-1411.
33. 33. Stupans I, Richards DA, McClure MT. Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 1995, 25, 1-8.
34. 34. Donelli MG, Franchi G, Rosso R. The effect of cytotoxic agents on drug metabolism. Eur J Cancer 1970, 6, 125-126.